Which COVID-19 Vaccine is Most Effective

Various types of COVID-19 vaccines have been approved to reduce the disease burden during the recent pandemic. To better appreciate differences, South Korean researchers conducted an observational study to evaluate the effectiveness of Novavax's NVX-CoV2373 and BNT162b2 vaccines in protecting adults.

This non-peer-reviewed study was published on February 19, 2023, and compared the results from 3,019 recipients of NVX-CoV2373 and 3,027 recipients of BNT162b2 vaccines.

The 40-week risk ratios for recipients of the NVX-CoV2373 vaccine compared with recipients of the BNT162b2 vaccine were 1.169 (95% CI, 1.015 to 1.347) for laboratory-confirmed SARS-CoV-2 infection.

And 0.504 (95% CI, 0.126 to 2.014) for severe SARS-CoV-2 infection.

The estimated risk of severe infection was 0.001 events per 1000 persons (95% CI, 0 to 0.003) for the NVX-CoV2373 vaccine and 0.002 events per 1000 persons (95% CI, 0.001 to 0.006) for the BNT162b2 vaccine.

These researchers wrote this 'study identifies the reduced risk of SARS-CoV-2 infection and severe infection after receipt of three doses of either NVX-CoV2373 or BNT162b2 vaccines in Korean adults.

The study authors did not declare any competing industry interest.